NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 268)
Posted On: 10/08/2018 4:43:35 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Strengthens IP Portfolio
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is building its strategic intellectual property (“IP”) portfolio with two recent Notices of Allowance from the U.S. Patent and Trademark Office (“USPTO”) as well as the addition of three new patents in Australia. The company anticipates receiving additional patents in the U.S. by the end of the year. An article discussing Lexaria reads, “If all are issued, LXRP will then hold 12 issued patents within its first patent family, “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof.” It would strengthen LXRP’s IP claims in both countries. All new Australian patents are projected to expire on June 10, 2035, it said. … LXRP has a growing IP portfolio and will license in any of the countries worldwide where its technology already has a patent or is patent-pending. DehydraTECH is its proprietary absorption technology platform. Based in British Columbia, Canada, LXRP is a biotechnology company that has developed technology that has shown faster and more effective delivery of cannabinoids and nicotine. Its IP portfolio already includes a patent for oral delivery of all cannabinoids.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is building its strategic intellectual property (“IP”) portfolio with two recent Notices of Allowance from the U.S. Patent and Trademark Office (“USPTO”) as well as the addition of three new patents in Australia. The company anticipates receiving additional patents in the U.S. by the end of the year. An article discussing Lexaria reads, “If all are issued, LXRP will then hold 12 issued patents within its first patent family, “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof.” It would strengthen LXRP’s IP claims in both countries. All new Australian patents are projected to expire on June 10, 2035, it said. … LXRP has a growing IP portfolio and will license in any of the countries worldwide where its technology already has a patent or is patent-pending. DehydraTECH is its proprietary absorption technology platform. Based in British Columbia, Canada, LXRP is a biotechnology company that has developed technology that has shown faster and more effective delivery of cannabinoids and nicotine. Its IP portfolio already includes a patent for oral delivery of all cannabinoids.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)